
    
      This is an international, multicenter (study conducted at multiple sites) study designed to
      estimate remission rates and assess treatment response, tolerability, and patterns of use of
      Paliperidone Palmitate 3-Month Formulation (PP3M) in a diverse population of participants
      with schizophrenia. The study will consist of a screening phase (Day -7 to Day 1), a 52-week,
      open-label, flexible-dose PP3M treatment phase and a follow up safety assessment 3 months (
      +/-14 days ) after the month 12 visit or early discontinuation. Participants' Safety will be
      monitored throughout the study.
    
  